What Happened?
Shares of diagnostic imaging company RadNet (NASDAQ: RDNT) fell 2.8% in the afternoon session after the company outlined strong growth plans and expressed confidence during an investor conference.
During a presentation at the KeyBanc Capital Markets Healthcare Forum, RadNet management showcased its strategic plans, anticipating revenue growth of 17% to 19% in its imaging centers and close to 50% in its digital health business for 2026. This optimism was built on a foundation of recent success, as the company had also reported record fourth-quarter revenue of $547.7 million, up 14.8% from the previous year. A key driver for the digital health expansion was the completed acquisition of Gleamer, which positioned RadNet's DeepHealth subsidiary as a global leader in radiology AI solutions. The company's Chief Financial Officer, Mark Stolper, underscored the positive sentiment, stating he had not been more excited about the business's position in his 21-year tenure.
The shares closed the day at $62.00, down 2.6% from previous close.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy RadNet? Access our full analysis report here, it’s free.
What Is The Market Telling Us
RadNet’s shares are quite volatile and have had 15 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The previous big move we wrote about was 5 days ago when the stock gained 3.4% on the news that the company presented a robust strategic outlook at the Barclays 28th Annual Global Healthcare Conference, projecting strong growth for 2026.
During the event, CFO Mark Stolper highlighted RadNet's significant revenue and EBITDA growth in 2025, which was driven by strong performance in advanced imaging. The company projected 2026 revenue to grow by 17%-19% and EBITDA to increase by 18%-22%. This positive company-specific news was supported by favorable trends in the broader medical imaging industry. The AI-Enabled X-Ray Imaging Solutions market, where RadNet is a key player, was expected to expand significantly. This growth reflected the company's strategic investments in technology to enhance its services in a competitive market.
RadNet is down 12.6% since the beginning of the year, and at $62.00 per share, it is trading 26.6% below its 52-week high of $84.48 from November 2025. Despite the year-to-date decline, investors who bought $1,000 worth of RadNet’s shares 5 years ago would now be looking at an investment worth $2,733.
ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.
AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.
